Antibody–drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Cellular Physiology"
DOI: 10.1002/jcp.27419
Abstract: Targeted delivery of therapeutic molecules into cancer cells is considered as a promising strategy to tackle cancer. Antibody–drug conjugates (ADCs), in which a monoclonal antibody (mAb) is conjugated to biologically active drugs through chemical linkers,… read more here.
Keywords: drug conjugates; drug; conjugates adcs; cancer ... See more keywords
Antibody Drug Conjugates (ADCs): Shaping the Future of Precision Oncology.
Sign Up to like & getrecommendations! Published in 2025 at "Anti-cancer agents in medicinal chemistry"
DOI: 10.2174/0118715206348204241128063329
Abstract: Antibody-drug conjugates (ADCs) are a groundbreaking advancement in targeted cancer therapy, combining the precision of monoclonal antibodies with the potency of cytotoxic drugs. This review first outlines the components of ADCs and their mechanisms of… read more here.
Keywords: oncology; precision; conjugates adcs; antibody drug ... See more keywords
Target Antigen Attributes and Their Contributions to Clinically Approved Antibody-Drug Conjugates (ADCs) in Haematopoietic and Solid Cancers
Sign Up to like & getrecommendations! Published in 2023 at "Cancers"
DOI: 10.3390/cancers15061845
Abstract: Simple Summary Antibody-Drug Conjugates (ADCs) provide effective anti-cancer treatments. ADC development requires the identification of appropriate tumour-associated antigens that can be targeted by the ADC to effectively kill cancer cells while minimising damage to healthy… read more here.
Keywords: clinically approved; drug conjugates; conjugates adcs; target antigen ... See more keywords